 |
67 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
342 Trials |  |
12240 News |  |
| «12...2829303132333435363738...229230» |
- bimiralisib (PQR309) / PIQUR, onvansertib (PCM-075) / Cardiff Oncology, Aliqopa (copanlisib) / Bayer
Concurrent inactivation of PI3K and PLK1 is synergistic and overcomes acquired resistance to PI3K inhibitors in NOTCH1MUT HNSCC (Section 20; Poster Board #5) - Mar 14, 2023 - Abstract #AACR2023AACR_4976;
We further tested the PLK1-specific inhibitor onvansertib (0-100nM) combined with pan-PI3K inhibitor copanlisib (0-200nM) or dual inhibitor bimiralisib (0-1?M). We will further validate this combination
- Synergistic efficacy of HSP90 and PI3K inhibitors in adrenocortical carcinoma (Section 14; Poster Board #20) - Mar 14, 2023 - Abstract #AACR2023AACR_4906;
Conclusively, combination of HSP90 and PI3K inhibitors demonstrated a promising in vitro synergistic efficacy by inhibiting the key oncogenic targets of ACC. Further validation of in vivo efficacy is warranted.
- Jaypirca (pirtobrutinib) / Eli Lilly
Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study (Section 47; Poster Board #29) - Mar 14, 2023 - Abstract #AACR2023AACR_4809;
Pirtobrutinib demonstrated promising preliminary efficacy and was well tolerated for patients who received prior RT-directed chemoimmunotherapy and covalent BTKi. Presented:ASH2022.
- Rubraca (rucaparib) / Clovis, Aliqopa (copanlisib) / Bayer
BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) (Section 47; Poster Board #20) - Mar 14, 2023 - Abstract #AACR2023AACR_4800;
P1/2
The RP2D was rucaparib 400mg BID with copanlisib 45mg (D1, D15; 28-day cycle) with signal of efficacy in patients with and without HRD. Clinical trial information: NCT04253262.
- Zydelig (idelalisib) / Gilead
Enhanced anti-breast tumor cancer activity using nano-formulated TLR 7/8 agonist and PI3K inhibitor (Section 23; Poster Board #14) - Mar 14, 2023 - Abstract #AACR2023AACR_3959;
were incorporated in poly(2-oxazoline) block copolymer polymeric micelle NPs...Enhanced adaptive T cell immunity against TNBCs and effective therapeutic improvement in immunocompetent mice following radiotherapy were only observed with simultaneous depletion of Tregs and MDSC. These data suggest radiotherapy in combination with nanoparticle co-delivery of immunomodulators inhibiting MDSCs and Treg, has promising potential for future clinical trials and translation for the treatment of TNBC patients.
- In vitro and in vivo synthetic lethality: Potent tumor suppression by a novel FLT3/cKIT/CSF1R/CDK19 inhibitor (Section 18; Poster Board #26) - Mar 14, 2023 - Abstract #AACR2023AACR_3912;
They synergized with anti-PD-1 and anti-CTLA-4 and led to tumor eradication and immunological memory formation. These studies identify novel allosteric inhibitors with potent synthetically lethal anti-tumor activity.
- Ibrance (palbociclib) / Pfizer, gedatolisib (PF-05212384) / Celcuity
A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1) (Section 46; Poster Board #21) - Mar 14, 2023 - Abstract #AACR2023AACR_3690;
P3
The trial is open for enrollment. This trial abstract was previously presented at the 2022 San Antonio Breast Cancer Symposium, December 6-10, 2022.
- Aliqopa (copanlisib) / Bayer, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Next-generation sequencing (NGS) and cytokine assessment from a phase III study of copanlisib in combination with rituximab in patients with indolent non-Hodgkin lymphoma (iNHL) - associations with survival endpoints (Section 47; Poster Board #10) - Mar 14, 2023 - Abstract #AACR2023AACR_3660;
Mutation status was associated with improvements in PFS in FL pts with mutant BCL2 or mutant EZH2 treated with C+R. iNHL pts with low plasma levels of IL2 levels treated with C+R showed a significant improvement in OS.
- pidnarulex (CX-5461) / Senhwa Biosci, Gilotrif (afatinib) / Boehringer Ingelheim
A user-friendly R Shiny app for predicting drug response of cancer using deep learning (Section 33; Poster Board #30) - Mar 14, 2023 - Abstract #AACR2023AACR_3355;
In summary, the present R Shiny app is a user-friendly platform that enables in silico drug screening using deep learning with no requirement of programming experience. We expect the tool to foster accessibility of our deep learning prediction machine and facilitate the process of drug development in cancer.
- Quantitative integration of PIK3CA hotspots and paralogy identifies occult oncogenic mutants in PIK3CD (Room W230 - Convention Center) - Mar 14, 2023 - Abstract #AACR2023AACR_3207;
inhibitors for patients with rare, yet druggable, oncogenic p110? mutations.
- Glycolysis is enriched to propagating waves in cell cortex as a new mechanism for cancer progression (Section 10; Poster Board #21) - Mar 14, 2023 - Abstract #AACR2023AACR_2812;
Cancer cells such as M3 had a larger drop in glycolysis than non-cancer parental M1 cells upon wave inhibition. These results provide a new explanation for the Warburg effect that increased cortical waves in cancer cells will accelerate and improve glycolysis, which will not only greatly contribute to our understanding of cancer but also the design of new interventions.
- Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B cell lymphoma models (Section 17; Poster Board #23) - Mar 14, 2023 - Abstract #AACR2023AACR_2552;
Results suggest that a combination with the CXCR4 inhibitor SPX5551 adds beneficial effect to BCR inhibitors and might overcome resistance to PI3K/BTK inhibitors. Adding SPX551 to the treatment of patients with B cell lymphoma warrants further exploration.
- Ibrance (palbociclib) / Pfizer, sapanisertib (CB-228) / Calithera
Elevated Akt/mTOR signaling drives therapy resistance in ALM (Section 15; Poster Board #14) - Mar 14, 2023 - Abstract #AACR2023AACR_2516;
CFAs with acquired-resistance cell lines also showed that combination inhibition decreased colony formation, showing the potential utility of concurrent CDK4i/6i and mTORi as an approach against acquired resistance. Our results show the efficacy of combined inhibition as an anti-tumor strategy.
- ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms (Section 14; Poster Board #20) - Mar 14, 2023 - Abstract #AACR2023AACR_2497;
Our results indicate that epigenetic plasticity led to the activation of HBEGF-ERBB signaling sustaining resistance to BTK/PI3K inhibitors, which can be overcome using epigenetic agents and ERBB inhibitors. These therapeutics approaches could be tested in novel clinical trials.
- | Journal: Hydrogen sulfide donor AP123 restores endothelial nitric oxide-dependent vascular function in hyperglycemia via a CREB-dependent pathway. (Pubmed Central) - Mar 14, 2023
Experiments performed in the aorta of CSE mice confirmed that reduced levels of HS not only negatively affect the CREB pathway but also impair Ach-induced vasodilation, significantly ameliorated by AP123. We have demonstrated that the endothelial dysfunction due to HG involves HS/PI3K/CREB/eNOS route, thus highlighting a novel aspect of the HS/NO interplay in the vasoactive response.
- | doxorubicin hydrochloride / Generic mfg.
Journal, IO biomarker: Piperine improves the sensitivity of osteosarcoma cells to doxorubicin by inducing apoptosis and inhibiting the PI3K/AKT/GSK-3? pathway. (Pubmed Central) - Mar 14, 2023
This study revealed for the first time that PIP can potentiate the sensitivity and cytotoxicity of DOX during osteosarcoma therapy in vitro and in vivo, which probably achieved by inhibiting the PI3K/AKT/GSK-3? signalling pathway.
- | STX-478 / Scorpion Therap
New P1/2 trial, Combination therapy, Monotherapy, Metastases: STX-478-101: First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 14, 2023
P1/2, N=160, Recruiting, Sponsor: Scorpion Therapeutics, Inc.
- | Journal: Microrna-206 induces hypoxic necrosis of femoral head by inhibiting VEGF/PI3K/AKT signaling pathway. (Pubmed Central) - Mar 14, 2023
This paper has provided an important research basis for the research of femoral head necrosis and the development of new diagnosis and therapeutic drugs for this kind of disease. It also has provided a reference for the further promotion of the chemotherapy drug delivery system.
- | Journal, PARP Biomarker, Synthetic lethality: PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality. (Pubmed Central) - Mar 14, 2023
We showed that PI3K/Akt1 pathway plays an important role in the sensitization of cancer cell lines with compromised function of ARID1A to PARPi treatment. We believe that using of PARPi monotherapy or in combination with radiation therapy is an appealing strategy for treating ARID1A-mutated cancers, as well as many other types of PI3K/Akt1-driven cancers.
- | Journal: RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells. (Pubmed Central) - Mar 13, 2023
Addition of the ROS scavenger glutathione to RIDR-PI-103 significantly rescued the cell proliferation in TDR cell lines while addition of the ROS inducer TBHP and RIDR-PI-103 inhibited cell proliferation in WM115 and WM983B TDR cell lines. Examining the efficacy of RIDR-PI-103 on BRAF and MEK inhibitor-resistant cells will expand possible treatment options and open avenues for the development of new ROS-based treatment therapies for BRAF-mutant melanoma patients.
- || Review, Journal: Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements. (Pubmed Central) - Mar 11, 2023
In this review, we report the results of the most recent and main ongoing studies evaluating pan-PI3K inhibitors and selective PI3K inhibitors in each breast cancer subtype. In addition, we discuss the future of their development, the various potential mechanisms of resistance to these inhibitors and the ways to circumvent them.
- | Journal: Recent updates of Indole derivatives as kinase inhibitors in the treatment of cancer. (Pubmed Central) - Mar 11, 2023
showed potent CDK5 inhibition by substituting 2nd and 6th position of indole ring. In the present review, we have summarized structure activity relationship (SAR) studies of Indole derivatives as kinase inhibitors for development of potential inhibitors.
- || Preclinical, Review, Journal: Phytochemicals and Nanoparticles in the Modulation of PI3K/ Akt/ mTOR Kinases and Its Implications in the Development and Progression of Gastrointestinal Cancers: A Review of Preclinical and Clinical Evidence. (Pubmed Central) - Mar 11, 2023
Phytochemicals are promising drug candidates for targeting the PI3K/mTOR pathway in various gastrointestinal cancer treatments. However, there is a need for extensive clinical studies to ascertain the commercial value of anticancer therapeutic compounds against cancers of the stomach, liver, and intestine.
- | Journal: Lead exposure induced developmental nephrotoxicity in Japanese quail (Coturnix japonica) via oxidative stress-based PI3K/AKT pathway inhibition and NF-?B pathway activation. (Pubmed Central) - Mar 10, 2023
Pb caused apoptotic increment by inhibiting the phosphatidylinositol-3-kinase (PI3K)/RAC-alpha serine/threonine-protein kinase (AKT) pathway and induced aggravated inflammation by activating Nuclear Factor kappa B (NF-?B) signaling pathway. The study implied that Pb caused nephrotoxicity through structural damages, uric acid metabolism disorder, oxidation imbalance, apoptosis and inflammatory pathway activation.
- | Preclinical, Journal: Hydroxysafflor yellow A regulates lymphangiogenesis and inflammation via the inhibition of PI3K on regulating AKT/mTOR and NF-?B pathway in macrophages to reduce atherosclerosis in ApoE-/- mice. (Pubmed Central) - Mar 9, 2023
The study implied that Pb caused nephrotoxicity through structural damages, uric acid metabolism disorder, oxidation imbalance, apoptosis and inflammatory pathway activation. HSYA affects inflammation and inflammation-associated lymphangiogenesis via suppressing PI3K to affect AKT/mTOR and NF-B pathway activation in macrophages, showing a comprehensive protective effect on atherosclerosis.
- || Review, Journal, CAR T-Cell Therapy: Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies. (Pubmed Central) - Mar 9, 2023
Protein kinase inhibitors, demethylating drugs, HDAC inhibitors, PI3K inhibitors, immunomodulatory drugs, Akt inhibitors, mTOR inhibitors, and Bcl-2 inhibitors exhibited potential synergy in combination with CAR-T cell therapy. In this review, we will discuss the recent application of these combination therapies for improved outcomes of CAR-T cell therapy.
- | Journal: miR-485-5p alleviates obstructive sleep apnea syndrome with hypertension by inhibiting PI3K/AKT signaling pathway via downregulating HIF3A expression. (Pubmed Central) - Mar 9, 2023
MiR-485-5p alleviates OSAS with hypertension by inhibiting the PI3K/Akt pathway via downregulating HIF3A expression through the PI3K/AKT pathway. These findings suggest that miR-485-5p has the potential for treating OSAS-associated hypertension.
- | Journal: Heat Shock Protein B7 Inhibits the Progression of Endometrial Carcinoma by Inhibiting PI3K/AKT/mTOR Pathway. (Pubmed Central) - Mar 9, 2023
HSPB7 was downregulated in EC and influenced EC cell proliferation, invasion, migration, and apoptosis via the PI3K/AKT/mTOR signaling pathway. These findings provide a novel perspective for the development of EC treatment strategies.
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Efficacy and Safety of Venetoclax+Rituximab in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of Bayesian Network Meta-Analysis () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1385;
OBJECTIVES: Venetoclax+rituximab (VEN+RTX) is a potent anti-leukemic therapy for relapsed/refractory chronic lymphocytic leukemia (R/R CLL), superior to bendamustine+rituximab (BEND+RTX) based on the results of the MURANO trial. The results of NMA suggest that VEN+RTX is superior to all chemoimmunotherapy and PI3K regimens and has similar efficacy to BTK inhibitors in R/R CLL.
- Risk of Richter Transformation in Relapsed/Refractory Cll: Results of Bayesian Network Meta-Analysis () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_813;
This study suggests that the choice of treatment regimen has no significant impact on the development of RT. The risk of RT is similar between chemoimmunotherapy, immunotherapy, and novel targeted therapies, including BTK and PI3K inhibitors and BCL-2 antagonists.
- ||| RLY-5836 / Relay Therap
New P1 trial, Combination therapy, Metastases: First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors (clinicaltrials.gov) - Mar 8, 2023
P1, N=220, Not yet recruiting, Sponsor: Relay Therapeutics, Inc.
- | Journal: Ras related protein Rab5a regulates complement C5a receptor trafficking, chemotaxis and chemokine secretion in human macrophages. (Pubmed Central) - Mar 8, 2023
Furthermore, C5a-induced secretion of proinflammatory chemokines (CCL2, CCL3) from HMDMs was attenuated by Rab5a or ?-arrestin2 knockdown, or by pharmacological inhibition with a C5aR1 antagonist or a PI3K inhibitor. These findings reveal a C5a-C5aR1-?-arrestin2-Rab5a-PI3K signalling pathway that regulates chemotaxis and proinflammatory chemokine secretion in HMDMs and suggest new ways of selectively modulating C5a-induced inflammatory outputs.
- | Preclinical, Journal: Novel insights in the pathomechanism of Brugada syndrome and fever-related type 1 ECG changes in a preclinical study using human-induced pluripotent stem cell-derived cardiomyocytes. (Pubmed Central) - Mar 8, 2023
The study demonstrated that the SCN5A variant (c.3148G>A/p.Ala1050Thr) caused loss-of-function of sodium channels and increased the channel sensitivity to high temperature and LPS challenge in hiPSC-CMs from a BrS cell line with this variant but not in two non-BrS hiPSC-CM lines. The results suggest that LPS may exacerbate BrS phenotype via enhancing autophagy, whereas fever may exacerbate BrS phenotype via inhibiting PKA-signalling in BrS cardiomyocytes with but probably not limited to this variant.
- | LY294002 / Eli Lilly, dovitinib (TKI258) / Allarity Therap, Oncoheroes
Journal, Machine learning: The combination of machine learning and transcriptomics reveals a novel megakaryopoiesis inducer, MO-A, that promotes thrombopoiesis by activating FGF1/FGFR1/PI3K/Akt/NF-?B signaling. (Pubmed Central) - Mar 7, 2023
Similarly, inhibition of PI3K-Akt signal pathway by its inhibitor LY294002 suppressed MK differentiation, and PI3K, Akt and NF-?B phosphorylation induced by MO-A. Taken together, our study provides an efficient drug discovery strategy for hematological diseases, and demonstrates that MO-A is a novel countermeasure for treating RIT through activation of the FGF1/FGFR1/PI3K/Akt/NF-?B signaling pathway.
- | LY294002 / Eli Lilly, gabapentin / Generic mfg.
Journal, IO biomarker: Gabapentin alleviates myocardial ischemia-reperfusion injury by increasing the protein expression of GABAAR. (Pubmed Central) - Mar 7, 2023
in the spinal cord. Gabapentin achieved a potent protective effect on the myocardium during the course of routine clinical treatment.
- | LY294002 / Eli Lilly
Journal: PI3K-Akt pathway-independent PIK3AP1 identified as a replication inhibitor of the African swine fever virus based on iTRAQ proteomic analysis. (Pubmed Central) - Mar 7, 2023
Moreover, LY294002, an inhibitor of the PI3K-Akt pathway, inhibited ASFV replication, indicating the importance of the PI3K-Akt pathway in ASFV infection. This study identified the network of interactions between ASFV and host cells and provides a reference for the development of anti-ASFV strategies and for studying the potential mechanisms and pathogenesis of ASFV infection.
- | Journal: Eremophilane-type and xanthanolide-type sesquiterpenes from the aerial parts of Xanthium sibiricum and their anti-inflammatory activities. (Pubmed Central) - Mar 7, 2023
Further investigation showed that xanthsibiriolide and 11?-hydroxyl-13-chloro-8-epi-xanthatin exerted their anti-inflammatory effects by inhibiting the PI3K/AKT/mTOR signaling pathway. Analysis of the structure-activity relationships indicated that the ?,?-unsaturated lactone ring and the 1,5-epoxide group might be the bioactive groups of xanthanolides, and these results provide a basis for further exploration of sesquiterpene-type lead compounds with anti-inflammatory activity.
- | Journal: Design, synthesis and biological evaluation of liposome entrapped iridium(III) complexes toward SGC-7901 cells. (Pubmed Central) - Mar 7, 2023
Western blotting showed that Ir1lipo and Ir2lipo inhibited PI3K (phosphoinositide-3 kinase), AKT (protein kinase B), p-AKT and activated Bcl-2 (B-cell lymphoma-2) protein and apoptosis-regulated factor caspase 3 (cysteinyl aspartate specific proteinase-3) and cleaving PARP (poly ADP-ribose polymerase). The results demonstrated that Ir1lipo and Ir2lipo induce cell apoptosis through targeting the endoplasmic reticulum (ER), cause oxidative stress damage, inhibiting PI3K/AKT signaling pathway, immunogenic cell death (ICD) and inhibit the cell growth at G2/M phase.
- | LY294002 / Eli Lilly
Preclinical, Journal: Neuregulin-1/PI3K signaling effects on oligodendrocyte proliferation, remyelination and behaviors deficit in a male mouse model of ischemic stroke. (Pubmed Central) - Mar 7, 2023
The neuroprotective effect of NRG1 is involved in its activation of PI3K/Akt signaling pathway via ErbB2, as shown by the suppression of the effect of NRG1 by the PI3K inhibitor LY294002. Our results demonstrate that NRG1 is effective in ameliorating the both acute phase neuroprotection and long-term neurological functions via resumption of neuronal proliferation and differentiation and oligodendrogliogenesis in a male mouse model of ischemic stroke.
- | Journal: Progranulin promotes proliferation, migration and invasion via the PI3K/Akt signalling pathway in a model of endometriosis. (Pubmed Central) - Mar 7, 2023
PGRN might promote the proliferation, invasion and migration of EUESC via the PI3K/Akt signalling pathway. These preliminary in-vitro findings may present a new perspective and inspire further study of the mechanism of EMS.
- || Review, Journal: Novel therapeutics in low-grade serous ovarian cancer. (Pubmed Central) - Mar 7, 2023
Additionally, recent trials have investigated combination therapies targeting the MAPK pathway, including MEK (mitogen-activated protein kinase kinase), BRAF (v-raf murine sarcoma viral oncogene homolog B1), FAK (focal adhesion kinase), and PI3K (phosphatidylinositol 3-kinase) inhibition. In this review, we will outline these novel therapeutic strategies for low-grade serous ovarian cancer.
- | Journal: Indirect bilirubin impairs invasion of osteosarcoma cells via inhibiting the PI3K/AKT/MMP-2 signaling pathway by suppressing intracellular ROS. (Pubmed Central) - Mar 7, 2023
IBIL may serve as an independent prognostic predictor for osteosarcoma patients. IBIL impairs invasion of osteosarcoma cells through repressing the PI3K/AKT/MMP-2 pathway by suppressing intracellular ROS, thus inhibiting its metastatic potential.
- | chloroquine phosphate / Generic mfg., LY294002 / Eli Lilly, MG132 / Jilin University, Dorothy M. Davis Heart and Lung Research Institute
Preclinical, Journal: ARID1B blocks methionine-stimulated mTOR activation to inhibit milk fat and protein synthesis in and proliferation of mouse mammary epithelial cells. (Pubmed Central) - Mar 6, 2023
To sum up, our data reveal that ARID1B is a key negative regulator of milk fat and protein synthesis in and proliferation of mammary epithelial cells, and blocks Met-stimulated mTOR gene transcription and protein phosphorylation. Our findings provide a new theoretical basis to utilize Met in milk production.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Journal: Dapagliflozin improves pancreatic islet function by attenuating microvascular endothelial dysfunction in type 2 diabetes. (Pubmed Central) - Mar 6, 2023
Dapagliflozin restores islet vascularisation and attenuates the inflammation of IMECs in type 2 diabetic mice. The dapagliflozin-induced improvement of
- | Journal: Identification of new candidate drugs for primary Sj (Pubmed Central) - Mar 4, 2023
The dapagliflozin-induced improvement of This first drug repositioning transcriptomic approach in Sj
- | Journal: Genetic and Physiological Effects of Insulin-Like Growth Factor-1 (IGF-1) on Human Urate Homeostasis. (Pubmed Central) - Mar 4, 2023
This first drug repositioning transcriptomic approach in Sj The combined results of infusion, genetics, and transport experiments suggest that IGF-1 reduces SU by activating urate secretory transporters and inhibiting insulin's action.
- | Piqray (alpelisib) / Novartis
Journal: The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer. (Pubmed Central) - Mar 4, 2023
Here we review the landscape of PIK3CA mutations in different cancers and efforts underway to define the functional properties of non-canonical PIK3CA mutations. In addition, we summarize what has been learned from clinical trials of PI3K inhibitors as well as current trials incorporating these molecular targeting agents.
- fluoxetine / Generic mfg.
Fluoxetine exerts anti-inflammatory effects on human epidermal keratinocytes, and suppresses endothelin release via inhibiting PI3K () - Mar 4, 2023 - Abstract #ISID2023ISID_1081;
Collectively, our findings demonstrate that FX (14 ?M) exerts potent anti-inflammatory effects, and suppresses the release of the endogenous itch mediator endothelins in human keratinocytes, most likely via the inhibition of PI3K. Thus, our data highlight the possibility of dermatological repositioning of FX to treat various inflammatory and pruritic dermatoses.
- A data-driven approach towards mature iPSC-derived keratinocytes () - Mar 4, 2023 - Abstract #ISID2023ISID_1052;
We postulate that the iKC maturity to become epidermal progenitor cells is key and requires further optimization of the culture medium composition based on our data on the small molecule targets. This will contribute to the future applicability of iPSCs as indefinite cell source for inflammatory skin disease modeling.